Prochlorperazine
| Clinical data | |
|---|---|
| Trade names | Compazine, Stemetil, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682116 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Oral administration, rectal administration, intramuscular injection, intravenous injection (IV) |
| Drug class | Typical antipsychotic |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Unknown, but presumed substantial |
| Protein binding | 91–99% |
| Metabolism | Mainly Liver (CYP2D6 and/or CYP3A4) |
| Elimination half-life | 4–8 hours, differs with the method of administration |
| Excretion | Bile duct, (colored) inactive metabolites in urine |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.345 |
| Chemical and physical data | |
| Formula | C20H24ClN3S |
| Molar mass | 373.94 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Prochlorperazine, formerly[4] sold under the brand name Compazine among others, is a medication used to treat nausea, migraines, schizophrenia, psychosis and anxiety.[5][6][7][8] It is a less preferred medication for anxiety.[5] It may be taken by mouth, rectally, injection into a vein, or injection into a muscle.[5]
Common side effects include sleepiness, blurry vision, low blood pressure, and dizziness.[5] Serious side effects may include movement disorders including tardive dyskinesia and neuroleptic malignant syndrome.[5] Use in pregnancy and breastfeeding is generally not recommended.[9] It is a typical antipsychotic which is believed to work by reducing the action of dopamine in the brain.[5]
Prochlorperazine was approved for medical use in the United States in 1956.[5] It is available as a generic medication.[6] In 2020, it was the 355th most commonly prescribed medication in the United States, with more than 600 thousand prescriptions.[10][11]
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ "Prochlorperazine 3 mg Buccal Tablets - Summary of Product Characteristics (SmPC)". (emc). 9 December 2019. Retrieved 30 December 2022.
- ^ "Buccastem M Buccal Tablets - Summary of Product Characteristics (SmPC)". (emc). 9 December 2019. Retrieved 30 December 2022.
- ^ "Side Effects of Compazine (Prochlorperazine), Warnings, Uses". RX List. Retrieved 14 April 2021.
- ^ a b c d e f g "Prochlorperazine Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- ^ a b British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 385–386. ISBN 9780857113382.
- ^ Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, Tepper D (June 2016). "Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies". Headache. 56 (6): 911–940. doi:10.1111/head.12835. PMID 27300483.
- ^ Din L, Preuss CV (March 2022). "Prochlorperazine". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 30725768.
- ^ "Prochlorperazine Use During Pregnancy". Drugs.com. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
- ^ "Prochlorperazine - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.